A posting on the now defunct Solano Pharmaceuticals website in August 2016 indicated Solano was developing disease-modifying therapeutics to target neurodegenerative diseases by optimizing compounds which target (ed) mitochondria, reduce(d) oxidative damage, and promote(d) neuronal survival. The companys lead therapeutic compound, XJB-5-131 was being developed for the treatment of Huntingtons, Alzheimers and Parkinsons. A Pitchbook listing for soon afterwards indicates the firm as Out of Business
